ARGX|argenx SE|Price:811.450|Chg%:-8.86

More Details of argenx SE Company

argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.

argenx SE Info



Ticker SymbolARGX

Company nameargenx SE

IPO dateJul 10, 2014

CEOvan Hauwermeiren (Tim)

Number of employees1599

Security typeDepository Receipt

Fiscal year-endJul 10

AddressLaarderhoogtweg 25

CityAMSTERDAM

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryNetherlands

Postal code1101 EB

Phone31763030

Websitehttps://www.argenx.com/

Ticker SymbolARGX

IPO dateJul 10, 2014

CEOvan Hauwermeiren (Tim)

Company Executives of argenx SE



Name

Name/Position

Position

Shareholding

Change

Mr. Tim van Hauwermeiren

Chief Executive Officer, Co-Founder, Executive Director

--

Mr. Peter K. M. Verhaeghe

Non-Executive Independent Chairman of the Board

--

Dr. Pamela M. (Pam) Klein

Non-Executive Independent Director

--

Mr. Anthony A. (Tony) Rosenberg

Non-Executive Independent Vice Chairman of the Board

--

Mr. James Michael (Jim) Daly

Non-Executive Independent Director

--

Mr. Arjen Lemmen

Vice President - Corporate Development and Strategy

--

Mrs. Andria Wilk

Global Head of Quality

--

Mr. Karl Gubitz

Chief Financial Officer

--

Ms. Malini Moorthy

General Counsel

--

Dr. Luc Truyen

Chief Medical Officer

--

Name

Name/Position

Position

Shareholding

Change

Mr. Tim van Hauwermeiren

Chief Executive Officer, Co-Founder, Executive Director

--

Mr. Peter K. M. Verhaeghe

Non-Executive Independent Chairman of the Board

--

Dr. Pamela M. (Pam) Klein

Non-Executive Independent Director

--

Mr. Anthony A. (Tony) Rosenberg

Non-Executive Independent Vice Chairman of the Board

--

Mr. James Michael (Jim) Daly

Non-Executive Independent Director

--

Mr. Arjen Lemmen

Vice President - Corporate Development and Strategy

--

Revenue Breakdown

Currency: USDUpdated: Tue, Jan 6

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Relevant data have not been disclosed by the company yet.

By RegionUSD

Name

Revenue

Proportion

United States

1.90B

86.56%

Rest of the World

161.25M

7.36%

Japan

89.39M

4.08%

China

43.52M

1.99%

Netherlands

153.00K

0.01%

By Business

By Region

Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Fri, Jan 16

Shareholders

Shareholder Types

Shareholders

Proportion

Fidelity Management & Research Company LLC

8.96%

T. Rowe Price Associates, Inc.

4.60%

Janus Henderson Investors

4.21%

Artisan Partners Limited Partnership

3.57%

Capital World Investors

3.20%

Other

75.46%

Shareholders

Proportion

Fidelity Management & Research Company LLC

8.96%

T. Rowe Price Associates, Inc.

4.60%

Janus Henderson Investors

4.21%

Artisan Partners Limited Partnership

3.57%

Capital World Investors

3.20%

Other

75.46%

Shareholder Types

Shareholders

Proportion

Investment Advisor

27.97%

Investment Advisor/Hedge Fund

16.89%

Hedge Fund

4.41%

Research Firm

1.10%

Pension Fund

0.39%

Private Equity

0.31%

Family Office

0.11%

Bank and Trust

0.09%

Other

48.74%

Institutional Shareholding



Updated: Mon, Dec 8

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q4

855

32.28M

58.19%

+72.85K

2025Q3

891

32.22M

58.55%

-544.28K

2025Q2

847

32.65M

61.10%

-1.53M

2025Q1

821

34.16M

62.26%

-3.81M

2024Q4

770

34.96M

63.31%

-1.04M

2024Q3

718

36.05M

63.46%

+556.56K

2024Q2

690

35.13M

62.09%

+253.45K

2024Q1

672

34.89M

59.82%

-632.92K

2023Q4

654

33.46M

57.06%

+708.68K

2023Q3

609

32.76M

55.78%

+1.52M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Fidelity Management & Research Company LLC

5.48M

8.96%

+264.63K

+5.08%

Sep 30, 2025

T. Rowe Price Associates, Inc.

2.81M

4.6%

-1.28M

-31.29%

Sep 30, 2025

Janus Henderson Investors

2.58M

4.21%

+9.85K

+0.38%

Sep 30, 2025

Artisan Partners Limited Partnership

2.19M

3.57%

-163.27K

-6.95%

Sep 30, 2025

Capital World Investors

1.96M

3.2%

+8.42K

+0.43%

Sep 30, 2025

Avoro Capital Advisors LLC

990.00K

1.62%

-185.00K

-15.74%

Sep 30, 2025

T. Rowe Price International Ltd

828.77K

1.35%

-59.10K

-6.66%

Sep 30, 2025

ClearBridge Investments, LLC

756.86K

1.24%

-16.00K

-2.07%

Sep 30, 2025

Wellington Management Company, LLP

729.99K

1.19%

+324.65K

+80.10%

Sep 30, 2025

Citadel Advisors LLC

713.56K

1.17%

-152.41K

-17.60%

Sep 30, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

VanEck Biotech ETF

5.04%

iShares Neuroscience and Healthcare ETF

4.22%

Goldman Sachs Future Health Care Equity ETF

3.92%

First Trust NYSE Arca Biotechnology Index Fund

3.45%

iShares Biotechnology ETF

3.12%

PGIM Jennison International Opportunities ETF

2.55%

ProShares Ultra Nasdaq Biotechnology

2.46%

Invesco Nasdaq Biotechnology ETF

2.44%

American Century Mid Cap Growth Impact ETF

1.63%

Invesco NASDAQ Next Gen 100 ETF

1.37%

VanEck Biotech ETF

Proportion5.04%

iShares Neuroscience and Healthcare ETF

Proportion4.22%

Goldman Sachs Future Health Care Equity ETF

Proportion3.92%

First Trust NYSE Arca Biotechnology Index Fund

Proportion3.45%

iShares Biotechnology ETF

Proportion3.12%

PGIM Jennison International Opportunities ETF

Proportion2.55%

ProShares Ultra Nasdaq Biotechnology

Proportion2.46%

Invesco Nasdaq Biotechnology ETF

Proportion2.44%

American Century Mid Cap Growth Impact ETF

Proportion1.63%

Invesco NASDAQ Next Gen 100 ETF

Proportion1.37%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

No Data

Date

Ex-dividend Date

Type

Ratio

No Data